AKAnna A. Kolodkina

Anna A. Kolodkina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna A. Kolodkina has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Congenital hyperinsulinism as part of a multisystem disease caused by a compound heterozygous variant in the YARS1 gene

    by Anna Bolmasova, Anna Zaretskaia, Sofia Mikhalina, Anna Postrigan, Anna Kolodkina, Valentina Peterkova

    Tyrosyl-transfer RNA (tRNA) synthetase, encoded by YARS1, is essential for protein synthesis, catalyzing the attachment of tyrosine to its cognate tRNA during translation. Pathogenic biallelic YARS1 variants cause infantile-onset multisystem neurological, endocrine, and pancreatic disease type 2 (IMNEPD2; OMIM #619418), an orphan disorder. Hypoglycemia in IMNEPD2 remains poorly characterized, with few reported cases. We describe an infant with a compound heterozygous YARS1 genotype (c.176T>C and c.1261G>A) who presented with severe hyperinsulinemic hypoglycemia, notable for a discordance between insulin and C-peptide concentrations and a lack of response to diazoxide and octreotide.


  • Open Access

    Clinical practice guidelines "Congenital hyperinsulinism"

    by A. V. Bolmasova, E. A. Yanar, I. L. Nikitina, A. A. Kolodkina, S. D. Mikhalina, V. A. Peterkova, O. B. Bezlepkina

    Congenital hyperinsulinism (CHI) is a rare, genetically heterogeneous disorder characterized by inappropriate hypersecre tion of insulin by pancreatic beta cells and is the most common cause of persistent hypoglycemia in young children. The in cidence of CHI in the general population ranges from 1:30,000 to 1:50,000 live births. Timely diagnosis and treatment of CHI are critical, as persistent hypoglycemia can lead to irreversible damage to the central nervous system. This review summa rizes current understanding of the etiology and pathogenesis of CHI and presents an up-to-date classification of CHI based on duration, etiology, histological form, and response to diazoxide therapy. A detailed diagnostic algorithm is provided, including provocative tests, molecular genetic testing, and imaging studies. The stages of conservative treatment and indi cations for surgical treatment are discussed. The review is based on updated clinical guidelines and is intended for practicing physicians — pediatricians, endocrinologists, and neonatologists — who care for children with hypoglycemic conditions.

  • Open Access

    Normophosphatemic familial tumoral calcinosis: description of a case with phosphate lowering therapy

    by A. V. Vitebskaya, Yu. V. Tikhonovich, A. A. Kolodkina

    Normophosphatemic familial tumoral calcinosis (NFTC) is characterized by cutaneous calcifications with no metabolic disorders; it manifests in the first years of life; associated with mutations in SAMD9 gene. Chronic trauma and transient hyperphosphatemia play a leading role in calcification formation. Surgical treatment can remove calcifications, but it does not prevent recurrence and can cause complications. Various conservative therapy is used. Lowering of blood phosphate levels is considered a promising pathogenetic treatment method. We present a clinical case of a patient with NFTC associated with the homozygous variant p.E1200K in SAMD9. A characteristic feature of our patient is the presence of multiple calcifications not only in the areas of injury (limbs), but also in areas of acne (face), as well as particularly active progression of the disease during puberty. A reduction in calcification size was observed after one year of continuous hypophosphatemic therapy (aluminum hydroxide and sevelamer 800 mg). The effectiveness of this therapy is debatable and limited by both poor patient tolerability of sevelamer and poor adherence. This is the first description of a patient with molecularly confirmed NFTC in Russia. A precise diagnosis allowed us to clarify the pathogenetic mechanism of calcification formation and propose treatment options.

  • Open Access

    A combination of endogenous hypercortisolism and primary hyperparathyroidism: clinical and genetic characteristics

    by E. O. Mamedova, E. G. Przhiyalkovskaya, L. Ya. Rozhinskaya, E. A. Yanar, I. S. Chugunov, A. A. Kolodkina, E. V. Vasilyev, A. N. Tiulpakov, Zh. E. Belaya, G. A. Melnichenko

    BACKGROUND : A combination of endogenous hypercortisolism and primary hyperparathyroidism (PHPT) occurs rarely, few clinical cases are described in the literature. The causes of the development of such combination are poorly investigated. AIM: To study clinical and genetic characteristics of a combination of endogenous hypercortisolism and PHPT. MATERIALS AND METHODS : A retrospective, single-center, cross-sectional, observational study was performed. Clinical characteristics of patients with a combination of endogenous hypercortisolism and PHPT were analyzed. All patients had previously undergone genetic testing as follows: MEN1 Sanger sequencing (n=10), next-generation sequencing of a panel of genes including MEN1 and CDKN1B (n=3), whole-exome sequencing (n=8). RESULTS : 21 patients (17 females, 4 males) were included in the study: 17 with Cushing’s disease (CD) and PHPT, 3 patients with Cushing’s syndrome (CS) and PHPT, and one patient with ACTH-ectopic syndrome (ACTH-ES) and PHPT. Among patients with CD and PHPT ten had MEN1 mutations (multiple endocrine neoplasia type 1 syndrome (MEN1)), and seven did not have MEN1 mutations (MEN1 phenocopies). In patients with MEN1 the debut of both CD and PHPT occurred at younger age in comparison to MEN1 phenocopies (p=0,015 and p=0,0006). In 60% of MEN1 CD occured in infancy, and in all children CD was the first manifestation. In 75% of adult MEN1 patients CD was diagnosed after PHPT, whereas in all MEN1 phenocopies PHPT was diagnosed after or during investigation with regard to CD. The majority of MEN1 patients also had gastro-entero- pancreatic neuroendocrine tumors (NETs), and some had lung NETs, whereas patients with MEN1 phenocopies did not have NETs. One patient with CS (bilateral lesions) and PHPT had ARMC5 mutation. In a patient with ACTH-ES and PHPT no mutations were found. CONCLUSION : A combination of endogenous hypercortisolism and PHPT occurs more frequently in females. In children with MEN1 and in MEN1 phenocopies the first manifestation is more frequently CD, while PHPT is diagnosed accidentally during evaluation, whereas in adults with MEN1 the first manifestation is more frequently PHPT. MEN1 mutations can be the cause of a combination of these two endocrine tumor diseases, and, possibly, ARMC5 mutations in cases of CS and PHPT, though in the majority of cases the cause remains unknown. Identification of causes of endogenous hypercortisolism and PHPT co-occurrence can expand our understanding of the mechanisms of endocrine tumor development.

  • Open Access

    Clinical practice guidelines "Congenital adrenal hyperplasia in children" with comments

    by I. S. Chugunov, I. V. Kopylova, A. A. Kolodkina, N. Yu. Kalinchenko, M. V. Vorontsova, O. B. Bezlepkina, V. A. Peterkova, N. G. Mokrysheva

    The clinical practice guidelines for congenital adrenal hyperplasia (CAH) in children clearly and systematically present the key information on the epidemiology, etiology, pathogenesis, and diagnostic methods for all forms of the disease. Protocols for glucocorticoid and mineralocorticoid replacement therapy, as well as follow-up regimens for patients in different age groups, are provided. These clinical guidelines were developed and approved by the expert community of pediatric endocrinologists from the Russian Association of Endocrinologists and endorsed by the council of the Russian Federation Ministry of Health. The guidelines are based on systematic reviews, meta-analyses, original articles, and scientific studies on this pathology conducted in the Russian Federation and other countries. This article provides updated author comments and clarifications on the most critical aspects of the diagnosis and treatment of congenital adrenal hyperplasia in childhood.


  • Open Access

    Complications of Pseudohypoparathyroidism and Congenital Forms of Hypoparathyroidism in Children

    by A. A. Dzhamaludinova, L. S. Sozaeva, N. V. Makazan, A. A. Kolodkina, K. S. Kulikova, N. Yu. Kalinchenko, A. V. Bolmasova, E. E. Novokreshennih, V. A. Peterkova, N. G. Mokrysheva

    BACKGROUND : Hypoparathyroidism (HypoPT) and pseudohypoparathyroidism (PHP) are rare, predominantly genetically determined diseases in children with similar complications, characterized by hypocalcemia and hyperphosphatemia. PHP and HypoPT have similar complications: brain and lens calcification. In HypoPT, there is also an increased risk of developing nephrocalcinosis. Data on the frequency and structure of complications in affected children in Russia are limited, and comparative studies are lacking. AIM : To compare the prevalence of chronic complications and to identify factors associated with their development in children with PHP and congenital forms of HypoPT. MATERIALS AND METHODS : A retrospective study with a prospective component included 135 children with PHP and congenital forms of HypoPT. The results of laboratory and instrumental studies were evaluated. RESULTS : At least one complication associated with HypoPT/PHP was identified in 82% of children. Nephrocalcinosis was most frequently detected in patients with autoimmune polyendocrine syndrome type 1 (APS-1) (67%) and autosomal dominant hypocalcemia type 1 (ADH1), and much less often in patients with PHP (22%) and unspecified forms of HypoPT (18%). Disease duration, as well as the duration of therapy with active vitamin D analogs and calcium supplements, was significantly longer in patients with nephrocalcinosis (p < 0.001). An association between nephrocalcinosis and cataracts was established (p=0.005). Hypercalciuria persisted in 60% of patients despite medical compensation, was most prevalent in APS-1 and ADH1, and was not observed in PHP (p < 0.001). No statistically significant relationship was identified between hypercalciuria and the development of nephrocalcinosis (p=0.567). A decrease in eGFR corresponding to CKD stage 2 was observed in 48.9% of patients. Fahr’s syndrome was detected in 76% of cases, predominantly involving the basal ganglia, and the presence of mineral deposits was associated with hyperphosphatemia (p=0.010). Cataract and micronephrolithiasis were less frequent (18.6% and 3.9%, respectively), with no significant differences between nosological groups. The most common lens opacities observed were cortical (68%) and posterior subcapsular (41%). The duration of the disease was longer in patients with cataracts (p = 0.018). CONCLUSION : Among the complications observed in children, nephrocalcinosis, hypercalciuria, and Fahr’s syndrome were the most frequent. Renal complications predominated in patients with APS-1 and ADH1. Hypercalciuria persisted despite optimal serum calcium levels in most patients.

  • A rare case of acrohygiantism caused by Carney’s complex: diagnostic and treatment challenges

    by E. E. Filkina, E. G. Przhiyalkovskaya, A. A. Kolodkina, L. S. Urusova, E. A. Troshina

    Acromegaly and gigantism are rare neuroendocrine diseases caused by excessive secretion of growth hormone (GH) and/ or high levels of insulin-like growth factor (IGF-1). Gigantism develops when excess GH or IGF-1 leads to accelerated linear growth before the completion of puberty and the closure of the epiphyses, most commonly caused by a somatotropic pituitary adenoma. The diagnosis of somatotropinoma in childhood is particularly challenging due to its subtle and nonspecific clinical presentation. Somatotropinomas at a young age are more often caused by genetic abnormalities and have a more aggressive course. The article presents a clinical case of acrogigantism in a patient with two identified heterozygous variants in the PRKAR1A and SDHB genes. The scientific interest of the described observation is due to the debut of gigantism in childhood, complex pathogenetic treatment, as well as the experience of using the growth hormone receptor antagonist pegvisomant in a teenager in Russia.

  • Hypothyroid myopathy and its association with MICU1 gene mutations: a clinical caseauthors

    by M. A. Perepelova, V. K. Slokva, E. A. Pigarova, A. S. Shutova, A. A. Kolodkina, A. V. Perepelov, L. K. Dzeranova

    Thyroid hormones are involved in the activation of glycogenolysis and mitochondrial oxidative phosphorylation. Kocher–Debré–Semelaigne Syndrome, also known as hypothyroid myopathy, is characterized by reduced glycogenolytic activity, leading to glycogen deposition in muscles. These reserves begin to deplete as euthyroidism is achieved. Primarily, patients complain of muscle weakness, mainly in the proximal muscle groups, stiffness, myalgia, and cramps. A distinctive feature of hypothyroid myopathies is the reversibility of clinical manifestations and a significant improvement in well-being with medical compensation of the disease. However, the absence of a pronounced clinical picture of hypothyroidism, combined with its rare occurrence, complicates early diagnosis and often requires differential diagnosis with other types of myopathies. This article presents a clinical case of a combination of genetically determined myopathy with extrapyramidal symptoms, associated with a mutation in the MICU1 gene, and hypothyroid myopathy associated with congenital hypothyroidism in a patient from a consanguineous marriage.

  • Exogenous Hyperandrogenism in Children due to Unintentional Exposure to Topical Androgens

    by Kristina S. Kulikova, Natalia Yu. Kalinchenko, Anna A. Kolodkina, Evgeniya V. Bublik, Anatoliy N. Tyulpakov

    Background. The usage of topical androgens has become increasingly popular in recent years due to their availability and ease of use at home. However, a lack of awareness about the precautions to be taken when using topical gels can lead to unintended secondary exposure of third parties, including the risk of developing exogenous hyperandrogenism in children. Case Reports describe 5 patients (3 boys and 2 girls) who were examined for signs of precocious sexual development (PSD): pubic hair, enlargement of the penis or clitoris, accelerated growth, and advanced bone age. All patients showed isolated increases in blood testosterone levels, low values of gonadotropic hormones, and other indicators of the steroid profile. During a repeated proactive survey of parents, it was revealed that the patients’ fathers were using transdermal forms of testosterone and were not following the precautions to avoid exposing their children to these products. After eliminating the exogenous exposure to androgen, all patients’ blood testosterone levels returned to prepubertal levels. During follow-up, two patients developed gonadotropin-dependent PSD, necessitating the initiation of triptorelin therapy. Conclusion. These case reports highlight the need for increased awareness among physicians and patients of the potential risk of developing exogenous hyperandrogenism in children with unintentional exposure to transdermal androgens as a result of parental or guardian use of these medications and, consequently, the importance of taking precautions. Thorough collection of family and social history in children with signs of precocious puberty is essential in the timely diagnosis of an exogenous cause of hyperandrogenism and in the selection of examination and treatment.